XML 27 R15.htm IDEA: XBRL DOCUMENT v3.10.0.1
Mezzanine and Stockholders' Equity
6 Months Ended
Jun. 30, 2018
Stockholders' Equity Note [Abstract]  
Stockholders' Equity
10.
Mezzanine and Stockholders’ Equity
 
All the historical NMM share and per share information has been adjusted to reflect the exchange ratio from the Merger (see Note 3).
 
Mezzanine
 
APC
 
As the redemption feature (see Note 2) of the shares is not solely within the control of APC, the equity of APC does not qualify as permanent equity and has been classified as noncontrolling interests in mezzanine or temporary equity.
 
Stockholders’ Equity
 
As of the date of this Quarterly Report on Form 10-Q, 751,067 holdback shares 
have not been issued 
to certain former NMM shareholders who were NMM shareholders at the time of Closing of the Merger, as 
they have yet to submit 
properly completed letters of transmittal 
to ApolloMed in order to 
receive their pro rata portion of ApolloMed common stock and warrants 
as contemplated under the Merger Agreement
.  Pending such receipt, such former NMM shareholders have the right to receive, without interest, their pro rata share of dividends or distributions with a record date after the effectiveness of the Merger. The condensed consolidated financial statements have treated such shares of common stock as outstanding, given the receipt of the letter of transmittal is considered perfunctory and the Company is legally obligated to issue these shares 
in connection with 
the Merger.
 
On March 21, 2018, the Company issued 37,593 shares of the Company’s common stock to the Company’s Chief Operating Officer for prior services rendered. The stock price on the date of issuance was $16.80, which resulted in the Company recording $631,562 of share-based compensation expense.
 
See options and warrants section below for common stock issued upon exercise of stock options and stock purchase warrants.
 
Options
 
The Company’s outstanding stock options consisted of the following:
 
  
Shares
  
Weighted
Average
Exercise Price
  
Weighted
Average
Remaining
Contractual
Term
(Years)
  
Aggregate
Intrinsic
Value
 
             
Options outstanding at January 1, 2018  1,141,040  $3.95   5.79  $19.81 
Options granted  155,000   9.85    -   - 
Options exercised  (301,036 )  3.87   -   16.63  
Options forfeited  (4,000 )  5.79   -   - 
                 
Options outstanding at June 30, 2018  991,004  $5.16   4.92  $20.70 
                 
Options exercisable at June 30, 2018  991,004  $5.16   4.92  $20.70 
 
During the six months ended June 30, 2018, stock options were exercised pursuant to the cashless exercise provision of the option agreement, with respect to 60,536 shares of the Company’s common stock, which resulted in the Company issuing 47,576 net shares.
 
During the six months June 30, 2018, stock options were exercised for 240,500 shares of the Company’s common stock, which resulted in proceeds of approximately $817,000. The exercise price ranged from $0.01 to $10.00 per share.
 
Outstanding stock options granted to primary care physicians to purchase shares of APC’s common stock consisted of the following:
  
  
Shares
  
Weighted
Average
Exercise Price
  
Weighted
Average
Remaining
Contractual
Term
(Years)
  
Aggregate
Intrinsic
Value
 
             
Options outstanding at January 1, 2018  853,800  $0.167   1.75  $508,864 
Options granted  -   -   -   - 
Options exercised  -   -   -   - 
Options expired/forfeited  -   -   -   - 
                 
Options outstanding at June 30, 2018  853,800  $0.167   1.25  $508,864 
                 
Options exercisable at June 30, 2018  853,800  $0.167   1.25  $508,864 
 
The aggregate intrinsic value is calculated as the difference between the exercise price and the estimated fair value of common stock as of June 30, 2018.
 
Share-based compensation expense related to option awards granted to primary care physicians to purchase shares of APC’s common stock, are recognized over their respective vesting periods,
 and 
consisted of the following:
  
  
Three Months Ended
June 30,
  
Six Months Ended
June 30,
 
  
2018
  
2017
  
2018
  
2017
 
Share-based compensation expense:                
Cost of services $-  $1,227  $-  $2,454 
General and administrative  202,382   320,006   404,764   640,012 
  $202,382  $321,233  $404,764  $642,466 
 
The remaining unrecognized share-based compensation expense of stock option awards granted to primary care physicians to purchase shares of APC’s common stock as of June 30, 2018 was $1,011,910, which is expected to be recognized over the remaining term of 1.25 years.
 
Warrants
 
The Company’s outstanding warrants consisted of the following:
 
  
Shares
  
Weighted
Average
Exercise Price
  
Weighted
Average
Remaining
Contractual
Term
(Years)
  
Aggregate
Intrinsic
Value
 
             
Warrants outstanding at January 1, 2018  3,648,541  $9.75   3.74  $14.25 
Warrants granted  -   -   -   - 
Warrants exercised  (210,625 )  7.27    -   10.46 
Warrants expired/forfeited  (11,250)  -   -   - 
                 
Warrants outstanding at June 30, 2018  3,426,666  $9.91   3.46  $15.95 
   
            
Weighted
 
      
Weighted
     
Average
 
      
Average
     
Exercise Price
 
Exercise Price Per
  
Warrants
  
Remaining
  
Warrants
  
Per
 
Share
  
Outstanding
  
Contractual Life
  
Exercisable
  
Share
 
              
$4.50   5,000   0.35   5,000  $4.50 
 9.00   1,116,111   2.28   1,116,111   9.00 
 10.00   1,455,555   3.80   1,455,555   10.00 
 11.00   850,000   4.44   850,000   11.00 
                   
$
4.50 –11.00
   3,426,666   3.46   3,426,666  $9.91 
 
During the six months ended June 30, 2018, common stock warrants were exercised for 210,625 shares of the Company’s common stock, which resulted in proceeds of approximately $1.5 million. The exercise price ranged from $4.00 to $10.00 per share.
 
Treasury Stock
 
APC owns 1,682,110 shares of ApolloMed’s common stock as of June 30, 2018 and December 31, 2017, which are legally issued and outstanding but excluded from shares of common stock outstanding in the condensed consolidated financial statements, as such shares are treated as treasury shares for accounting purposes.
 
Dividends
 
During the first quarter of 2018, APC distributed $2,000,000 of dividends to APC shareholders.
 
In April 2018, NMM distributed approximately $10,000,000 to former NMM shareholders, from the $18,000,000 that was previously classified as restricted cash and dividends payable. As of June 30, 2018, $8,000,000 of restricted cash remains from the Merger, and are still held for distribution.